Multiple sclerosis (MS) is a chronic, incurable demyelinating disease of the central nervous system (CNS) that is estimated to affect 2.5 million people worldwide (National Multiple Sclerosis Society, n.d.). MS frequently occurs in people who are 20-50 years of age and is the most common cause of acquired neurological disability in young people. Recent data show that treatment initiated when the first signs of MS appear can reduce later disability (Kappos et al., 2007) , underscoring the need for rapid and accurate diagnosis.
For many patients, presenting with a clinically isolated syndrome (CIS)-a first neurologic episode that can be attributed to demyelination-is the first indication of potential MS. This often manifests in one of the following ways: optic neuritis, which may be demonstrated by impaired or complete loss of vision in one eye; sensory deficits, such as numbness in the face and neck area; pyramidal symptoms, usually unilateral, which can range from mild-to-severe weakness; or brainstem symptoms, such as severe dizziness, nausea, and vomiting. Many patients who experience a CIS, particularly those with abnormal MRI findings, go on to develop clinically definite MS (CDMS; Comi et al., 2001; Galetta, 2001; Kappos et al., 2006; Tintoré et al., 2006) , which often begins a pattern of relapse and remission. A multifocal CIS presentation (in which the patient's symptoms suggest the presence of more than one CNS lesion) is a particularly ominous indicator of future MS. For example, before a CIS diagnosis was made, one of our patients was hospitalized due to severe cerebellar and brainstem symptoms, an inability to stand, severe nausea and vomiting, and unilateral weakness. She later was found to have multiple T1 and T2 lesions.
The relapsing-remitting phase of MS (RRMS) is characterized by acute episodes of neurologic dysfunction followed by periods of relative clinical stability during which patients may have complete or partial remission. In as many as 90% of patients, RRMS is followed by a secondary phase of progressive disability, secondary progressive MS (SPMS; Weinshenker et al., 1989) , during which relapses still may occur. In a minority of patients, MS begins with a progressive pattern with continual gradual worsening of neurologic impairment, upon which relapses later may be superimposed. A retrospective study of data from the Lyons MS database found Early Interferon Beta Treatment in Multiple Sclerosis: Nursing Care Implications of the BENEFIT Study Ute H. Webb Abstract: Interferon beta (IFNb) is a first-line treatment for relapsing forms of multiple sclerosis (MS) that can reduce the rate of clinical attacks and limit disability progression. Recent trials have shown that initiating IFNb treatment at the time of the first clinical event suggesting MS can delay the onset of clinically definite MS and, in the case of IFNb-1b, inhibit the progression of later disability. These findings have led to a trend toward earlier treatment initiation in clinical practice. While trials show good levels of adherence to therapy, there often is room for improvement in the clinical setting. Managing MS symptoms and treatment-related adverse events and providing patient education are vital to optimize adherence, and nurses can employ a number of strategies as part of the support program to ensure patients gain the most benefit from their treatment. In addition to providing a great deal of evidence supporting early MS treatment, the ongoing BEtaseron in Newly Emerging multiple sclerosis For Initial Treatment (BENEFIT) study has highlighted the fact that IFNb can be well tolerated, especially with correct management. This article summarizes the lessons learned from the BENEFIT study, and the ways in which nurses can incorporate this knowledge into clinical practice. that 8.6% of patients had a progressive initial course (Confavreux, Vukusic, Moreau, & Adeleine, 2000) .
Available Therapies for RRMS
Several disease-modifying drugs (DMDs) now are available to treat RRMS. The first-line treatments are three formulations of interferon beta (IFNb) and one formulation of glatiramer acetate (GA). Mitoxantrone (Novantrone) also is approved for RRMS treatment, although its attendant risks may outweigh its clinical benefit (Goodin et al., 2002) . Similarly, natalizumab (Tysabri) is licensed for treatment of RRMS, but it generally is considered a second-line therapy for patients who are refractory to other treatments (Ransohoff, 2007) . Table 1 Group, 1993; Jacobs et al., 1996; Johnson et al., 1995; PRISMS Study Group, 1998 ). These agents also effectively limit the development of brain lesions as seen on MRI scans, as well as delay the progression of disability in patients with RRMS (IFNB Multiple Sclerosis Study Group; Jacobs et al., 1996; Johnson et al.; PRISMS Study Group; Wolinsky et al., 2002) . In the clinical setting, individual outcomes range from complete response (no disease activity on therapy) to reasonable response (in line with clinical trial outcomes) to active disease despite therapy. When a patient does not respond to therapy, it is impossible to tell if this is attributable to high disease activity, poor adherence, or a shortcoming in treatment. Currently, there is no comprehensive guideline on how to define and react to suboptimal responses to treatment. Physicians must judge the relative success of therapy in individual patients, consider the available evidence, and weigh the possible advantages of treatment modification (Freedman et al., 2004) .
Early MS Treatment
A great deal of irreversible damage to the CNS occurs early in the course of MS (Brex et al., 2001; Kuhlmann, Lingfeld, Bitsch, Schuchardt, & Brück, 2002) ; this damage may be responsible for later disability (De Stefano et al., 2001 ). Most patients with CIS, especially those with an abnormal MRI scan, rapidly go on to develop CDMS (Comi et al., 2001; Confavreux & Vukusic, 2006; Galetta, 2001; Jacobs et al., 2000; Kappos et al., 2006; Tintoré et al., 2006) . The BEtaseron in Newly Emerging multiple sclerosis For Initial Treatment (BENEFIT) study is the only study to date that has evaluated the time to MS as defined by the McDonald Criteria (McDonald et al., 2001) . BENEFIT showed that placebo-treated patients with CIS had a 50% risk of developing McDonald MS after 6 months, and this risk increased to 85% by 2 years (Kappos et al., 2006) .
DMDs are most effective when therapy is initiated promptly. As the first sign of potential MS, CIS represents the earliest opportunity for treatment initiation. Results of recent studies on patients with CIS have led to a paradigm shift toward IFNb treatment in patients at the time of the first clinical event suggestive of MS.
Three randomized, placebo-controlled studies have shown that IFNb treatment can delay conversion to CDMS (Comi et al., 2001; Jacobs et al., 2000; Kappos et al., 2006) . Most recently, the BENEFIT study showed that patients treated with IFNb-1b 250 µg subcutaneously (SC) every other day had 50% reduced risk for developing CDMS (at 2 years) compared with placebo (Kappos et al., 2006) . The BENEFIT study also showed that IFNb-1b treatment delays the onset of MS as defined by the McDonald criteria: IFNb-1b was associated with a 46% reduction in the risk of progression to McDonald MS within 2 years compared with placebo (Kappos et al., 2006) . No data are available on the use of GA in patients with CIS, although such a study currently is in progress. A follow-up phase of the BENEFIT study in which enrolled patients are offered IFNb-1b for up to 5 years after the first study drug injection (randomization) is underway. Ninety-six percent of the original study population chose to enter the follow-up phase (Kappos et al., 2006) and all patients recently completed 3 years of follow-up. An integrated analysis of data up to this point (Kappos et al., 2007) has shown that the earlytreatment group (those originally randomized to IFNb-1b in the placebo-controlled phase) had a 40% reduction in the risk of disability progression compared with the delayed-treatment group (those originally allocated to placebo but given IFNb-1b in the follow-up study). The BENEFIT study is the first to demonstrate that treating patients shortly after the first clinical event indicative of MS can positively affect subsequent disability progression. This analysis also confirmed the results of the placebo-controlled phase, showing that early treatment reduced the risk of CDMS over 3 years by 41%. The Functional Assessment of MS instrument found no significant difference in health-related quality of life (HRQoL) between the two groups. However, at 3 years, the early-treatment group showed an improvement in HRQoL from baseline as measured by the EuroQol 5-Dimensional questionnaire, whereas scores in the delayed-treatment group had fallen (Fig 1) . Neurological function was measured using the Multiple Sclerosis Functional Composite (MSFC) scale. Scores improved in most patients, and although there was no difference between the two groups regarding the scale as a whole at 3 years, the early-treatment group performed significantly better than patients who received delayed treatment in the cognitive function subtest of the MSFC (Kappos et al., 2007) .
Tolerability of IFNb-1b in the BENEFIT Study and Strategies to Minimize Adverse Events
Adverse events (AEs) can occur in patients treated with any disease-modifying therapy for MS. With GA therapy, reported side effects include injectionsite reactions, vasodilation, and chest pain. Some patients also have reported an acute vasomotor reaction involving palpitations, muscle tightness, difficulty breathing, and anxiety (Bornstein et al., 1991; Johnson et al., 1995) . Lipoatrophy also can occur at GA injection sites, causing disfigurement that is thought to be permanent (Edgar, Brunet, Fenton, McBride, & Green, 2004; Soos, Shakery, & Mrowietz, 2004) .
The most commonly reported AEs associated with IFNb treatment include pain and reactions at injection sites and influenza-like symptoms. The Betaseron versus Rebif InvestigatinG Higher Tolerability (BRIGHT) study compared frequency of injection-site pain and reactions in patients treated with IFNb-1b 250 bg SC every other day or IFNb1a 44 bg three times weekly. Patients treated with IFNb-1b reported significantly less pain than patients receiving IFNb-1a, and they had fewer injection-site reactions (Baum et al., 2007) .
To maximize the tolerability of IFNb-1b in the BENEFIT study, the dose was gradually increased at the start of treatment; four dose steps of 62.5 bg were given every fourth injection, up to the full dose of 250 bg. During the first 3 months of treatment, concomitant ibuprofen or acetaminophen were administered to reduce influenza-like symptoms. In countries where they were approved, autoinjector devices were used to minimize injection-site reactions (Kappos et al., 2006) . Previous studies have shown that using an autoinjector can reduce the frequency and intensity of injection-site reactions (Brochet, Lemaire, Beddiaf, & the EPICURE Study Group, 2006; Burks, 2005) .
Few patients withdrew from the placebo-controlled phase of the BENEFIT study (5.7% of patients taking placebo and 7.2% of patients taking IFNb-1b), indicating the study medication was well tolerated. Adherence to study medication was excellent, with more than 97% of patients in each group receiving at least 80% of scheduled treatments. The tolerability of IFNb-1b was supported by the fact that 96% of all patients chose to receive open-label treatment in the follow-up study. The most commonly reported treatment-associated AEs in the BENEFIT study were injection-site reactions and influenza-like symptoms. The incidence of each of these diminished over time, being substantially lower in the second year of the study than in the first year (Kappos et al., 2006) . Over 3 years, the reported frequencies of AEs were within the established safety and tolerability profile for IFNb-1b (Table 3 ). In our clinic, IFNb-1b was well tolerated by most BENEFIT patients. No patient has yet withdrawn due to AEs, although 1 patient had treatment temporarily suspended because of grade IV liver toxicity. She was rechallenged after her liver enzymes returned to normal; after gradual titration up to full dose, her enzyme levels have remained stable.
In the majority of patients treated with IFNb, AE frequency decreases spontaneously over time. In any patient, regardless of disease stage, the time interval occurring before AEs diminish is critical, as it represents a window during which patients may be more likely to withdraw from treatment. The support nurses can extend to patients to help preserve adherence is especially important at this time. The measures to reduce AEs that were incorporated in the design of the BENEFIT study may have contributed to adherence during this period.
In our clinic, the fact that BENEFIT patients did not have a definite MS diagnosis was somewhat challenging. At every visit, we asked patients if they wanted to continue to participate in the study. Some patients who had not experienced new symptoms were relieved the therapy appeared to be working, Note. Frequently reported is defined as being reported by at least 10% of patients. The incidence displayed is the number of patients reporting the adverse event (or having the respective laboratory change) at least once.
but others questioned the value of continuing, particularly if they were experiencing persistent influenza-like symptoms. Many of our patients enrolled in the BENEFIT study asked to see their MRI results, but this was not allowed because of the strict double-blinded design of the study. It was especially difficult to not be able to provide any patientspecific information at the end of the 2-year placebocontrolled phase. Before the start of the open-label extension phase, however, blinding was removed for patients on placebo who had no MRI activity. This procedure helped to reassure patients who were considering entering the follow-up phase.
The Nursing Role in Managing MS Symptoms

Minimizing the Impact of MS Symptoms
In many Canadian centers, nurses are patients' primary contact and source of information, and they are involved actively in a patient's care from the start. The patient-nurse relationship is based necessarily on mutual trust and respect, and nurses play an important role in helping patients remain motivated and adhere to long-term treatment. MS-related symptoms such as fatigue, bladder and bowel dysfunction, and motor and cognitive deficits can strongly affect a patient's life. The symptoms' effects on patients can be minimized with appropriate management and coping strategies, and MS nurses can help them implement these strategies. Unfortunately, many patients deny the need for self-care strategies. For example, they may refuse to use ambulatory aids (because this makes their condition visible to others) or they may not disclose their condition for fear of losing their job. Patients in denial often have poor coping skills and some will not accept help even in the face of overwhelming fatigue. MS nurses can skillfully help patients accept their condition, which can entail a long and difficult journey. MS self-help patient groups also can be an important source of help and encouragement, although they do not suit all patients.
The Decision to Treat
In consultation with a neurologist, patients need to decide if they want to initiate treatment at the time they present with a CIS; nurses simultaneously play a vital role in supplying patients with the facts they need to make informed decisions. Nurses can provide the most up-to-date information on the statistical risk of developing MS and emphasize that early treatment has been shown to make a significant difference in outcome. The CNS damage resulting from MS is irreversible, and loss of function cannot be restored later. Experience tells us that DMDs appear to be more effective the earlier the treatment is started. On the other hand, patients should be informed that an individual's future disease course cannot be predicted, and that DMDs for MS often are associated with side effects that can be effectively mitigated with management strategies. The decision whether to initiate therapy always must be driven by the patient, and his or her choice must be supported by the nurse and physician. Similarly, once a patient has elected to begin therapy, he or she needs to make an informed choice among available drugs, and this decision also must be supported by the care team. In a supportive environment, a patient who makes informed decisions regarding his or her disease management is more likely to adhere to therapy.
Optimizing Treatment Efficacy
After a patient begins treatment, he or she must adhere to the regimen to gain its full benefit; any treatment can only be fully effective in adherent patients. Although clinical trials such as BENEFIT show it is possible to achieve high levels of adherence to therapy, this is not always the case in the clinical setting, particularly in the long term. Optimizing and maintaining patient adherence is one of the major challenges facing the clinical care team. At our clinic, levels of adherence are encouraging: most patients do not miss any injections, and some miss only a few (on average, 2-3 per month for frequently administered therapies). Nurses are key providers of patient education, which is vital to maintain acceptance of and adherence to therapy. Areas in which nurses can provide information include correct treatment self-administration, ways to reduce the risk of AEs, and self-care strategies to minimize the impact of MS on everyday life. Nurses also can advise patients on the availability of support services outside the clinical-care setting, such as counseling. In our clinic, we are fortunate to have a family counselor who has a great deal of experience with patients with MS. Our physicians and nurses encourage patients to accept counseling. It is important that support is maintained over the long-term to ensure patients remain motivated to continue taking their medication.
Conclusions
Clinical trials have shown that early initiation of IFNb treatment lowers the risk of conversion to CDMS. As a result, patients can be treated with IFNb at the time of a first event suggestive of MS if their MRI scan shows they are at high risk of CDMS. The BENEFIT study has demonstrated that IFNb-1b can delay the onset of CDMS when administered at this early stage, and it is well tolerated in this patient population (Kappos et al., 2006 ). An analysis of combined data from the BENEFIT placebo-controlled and follow-up phases after 3 years has demonstrated that early initiation of IFNb-1b treatment prevents the development of confirmed disability, a critically important result supporting its use in patients with a first event suggestive of MS (Kappos et al., 2007) . The followup phase of the BENEFIT study is ongoing, and the final results may show further evidence supporting early IFNb-1b treatment.
A patient's decision to initiate treatment and adhere to that therapy is vital to optimize efficacy. MS nurses play a central role in ensuring adherence to treatment by working closely with patients to provide information, support, and education to help manage their IFNb therapy. Measures to minimize treatment-related AEs are especially important to optimize adherence. These measures include the use of dose-titration and concomitant medication to reduce influenza-like symptoms and autoinjector devices to reduce injection-site reactions. With appropriate support from the clinical care team, particularly nurses, patients can achieve the high levels of adherence reported by clinical trials and experience the full benefits of their medication.
